NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the stock exchange announcement published by BerGenBio ASA
(the "Company") on 25 April 2023 with key information relating to the
preferential rights issue in the Company.

Date on which the terms and conditions of the preferential rights issue were
announced: 25 April 2023 and 20 May 2023

Last day including right: 22 May 2023

Ex-date: 23 May 2023

Record Date: 24 May 2023

Date of approval: 22 May 2023

Maximum number of new shares: 2,500,000,000

Subscription price: NOK 0.10

Ratio preferential rights: Each existing shareholder as of 22 May 2023 (and
being registered as such in Euronext Securities Oslo, the Norwegian Central
Securities Depository, (the VPS) as at the expiry of 24 May 2023 (the record
date)) will be granted 28.197440 subscription rights for each share registered
as held by the shareholder. The number of subscription rights granted to each
existing shareholder will be rounded down to the nearest whole subscription
right.

Subscription ratio: 1:1 (number of new shares per subscription right)

Managers: Arctic Securities AS and Carnegie AS

Will the rights be listed: Yes (ticker code "BGBIT")

ISIN for the preferential rights: ISIN NO 0012921180

Other information: The subscribers in the Rights Issue will without cost be
allocated one warrant (Nw. "frittstående tegningsrett") issued by the Company
for every two new shares allocated to, and paid by, them in the Rights Issue.
The number of warrants to be issued will be minimum 843,750,000 and maximum
1,250,000,000. Each warrant will give the holder a right to subscribe for one
new share in the Company at a subscription price equal to the volume-weighted
average price (VWAP) of the Company's shares on the Oslo Stock Exchange on the
three last trading days prior to the first date on which the holder can exercise
the warrant in each exercise period (as described below) less 30%, but in any
event not exceeding the subscription price in the Rights Issue plus 30% (i.e.
NOK 0.13. The warrants may be exercised during two exercise periods: (i) within
the first 14 days after the Company's announcement of its Q3 2023 quarterly
financial report and (ii) from 1 April 2024 to 14 April 2024.

The preferential rights issue is subject to approval by the annual general
meeting of the Company, which will be held on 22 May 2023.

This information is published in accordance with the requirements of the
Continuing Obligations.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

For information about the Rights Issue please contact the Managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.